Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.35 |
| ▸ | FEN1 | P39748 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 2/20 | 0.35 |
| ▸ | CHUK | O15111 | 2/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.33 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748092 | 0.91 | ALDH1A1 (0.40) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL20940189 | 0.80 | ALDH1A1 (0.38) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL19747518 | 0.77 | ALDH1A1 (0.32) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL17203142 | 0.71 | PIK3CG (0.48) | IKBKBCHUKPIK3CGPIK3CAPIK3CD | |
| SCHEMBL19747741 | 0.71 | CA1 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL19747511 | 0.71 | IKBKB (0.35) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL17203853 | 0.70 | PIK3CG (0.47) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL17203037 | 0.70 | PIK3CG (0.46) | ALDH1A1ALOX5APFEN1CYP2C19IKBKB | |
| SCHEMBL17204003 | 0.70 | KMT2A (0.51) | ALDH1A1CYP2C19IKBKBCHUKNEK1 | |
| SCHEMBL17203800 | 0.69 | IKBKB (0.44) | IKBKBCHUKNEK1PIK3CGPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-08-11 | — | — | US | disclosed |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-04-02 | — | — | US | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017223414-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | ALDH1A1 1354/4885ALOX5AP 2939/4885FEN1 1812/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | ALDH1A1 1774/4885ALOX5AP 3317/4885FEN1 2266/4885 |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | ALDH1A1 3638/4885ALOX5AP 2472/4885FEN1 2794/4885 |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | PIK3CA, PIK3CG, PIK3CD | ALDH1A1 1168/4885ALOX5AP 3337/4885FEN1 1566/4885 |
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | ALDH1A1 2818/4885ALOX5AP 3045/4885FEN1 2882/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | ALDH1A1 3638/4885ALOX5AP 2472/4885FEN1 2794/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | ALDH1A1 3638/4885ALOX5AP 2472/4885FEN1 2794/4885 |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | ALDH1A1 3638/4885ALOX5AP 2472/4885FEN1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.